Need extra support quickly? We are working with clients around the world right now to help them tackle new challenges from COVID-19. How can we help you? Learn More >

Back to Posts

Back to Posts

November 25, 2019 Life Science Consulting

Analytical Methods for the Investigation of Carcinogenic Nitrosamines in APIs and Drug Products

Ewelina Czerniec-Michalik ProPharma Group

Since September 26, 2019, all EU Marketing Authorization Holders (MAHs) of medicines for human use are facing what might be regarded as a new requirement: review their drug products on the possible presence of nitrosamines. The associated risk evaluation should be finalized by MAHs before March 26, 2020. In case of the identification of the risk of nitrosamine formation, MAHs should test drug products and APIs using sensitive and validated analytical methods.

Testing of medicines identified to be at risk should be concluded at the latest before September 19, 2022, three (3) years after the publication of the EMA notification. Products identified as high priority should be tested as soon as possible. The outcome of the analysis of multiple products from different MAHs will be evaluated by Competent Authorities and will be used for investigating the root cause of nitrosamine formation.

Based on the final legally binding decision of the European Commission, European Pharmacopa monographs of valsartan, candesartan, irbesartan, losartan, and olmesartan were revised setting limits for N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) given in Table 1. New monographs are scheduled for implementation on January 1, 2020. Similar interim specification limits were set by the Food and Drug Administration (FDA). Products containing NDMA or NDEA above these limits or containing both impurities at any level will have to be withdrawn from the market. After the transition period of 2 years, a strict limit of < 0.03 ppm for NDMA and NDEA will apply. Other nitrosamines which may be potentially present in “sartans” are e.g. N-nitrosoethylisopropylamine (EIPNA), N-nitrodiisopropylamine (DIPNA) and 4-[methyl(nitroso)aminobutanoic acid (NMBA).

Table 1 Nitrosamine impurities interim limits in common “sartans”

There are several analytical methods which can be utilised for the testing of APIs and finished drug formulations for the presence of nitrosamines, published by the Official Medicines Control Laboratories (OMCLs), FDA, Health Canada, and Singaporean Health Sciences Authority (HSA). The overview of these methods is provided in Table 2. The methods for testing of nitrosamines in “sartans” involve the use of chromatographic techniques (reversed phase liquid chromatography – RP-LC or gas chromatography – GC), combined with mass spectrometry (MS), spectrophotometry (UV) or nitrogen chemiluminescence (NCD). The identification and accurate quantification of impurities using MS often requires use of isotope labelled internal standards. Reference standards of nitrosamines can be obtained in the ready-to-use methanol solutions, which limit the exposure of analysts to potentially carcinogenic substances. Sample material has to be homogenised, extracted and filtered prior to analysis. Nitrosamines are known to be light sensitive, therefore samples should be prepared freshly before testing and the use of amber glassware or other protection against the light is recommended. Some nitrosamines may also degrade at elevated temperatures, e.g. applied in the GC inlet. The suitable sample pre-treatment and use of protective pre-columns should be considered.

Special attention should be given to the specificity of selected analytical methods, considering various sample matrices and the interference of sample compounds with investigated impurities. Analysis of model, spiked solutions, and real product samples with the subsequent evaluation of peak resolution and analyte recovery will increase the reliability of the method. Usually, the simple sample handling workflow, without complex extraction or separation procedures and selection of commonly used techniques results in the development of cost-effective, robust, and reproducible methods, which can be applied in the routine analysis. All methods used for the assessment of nitrosamines in APIs and drug products should be validated as per ICH Q2 guideline.

Table 2 Overview of published methods for nitrosamine impurities analysis in APIs and drug products  (click to view larger image)

Related Posts
EVENTS

Your Business has Complex Challenges. ProPharma Group has Exceptional Solutions.

We partner with pharmaceutical, biotechnology, and medical device clients to tackle complex challenges. Contact us to learn how our experienced team can help ensure regulatory and development success throughout the product lifecycle.

Interested in gaining an industry edge? Let us help you stay up to date.


All fields are required.